Samenvatting
Recent clinical trials for H3K27-altered diffuse midline gliomas (DMGs) have shown much promise. We present a consensus roadmap and identify three major barriers: (1) refinement of experimental models to include immune and brain-specific components; (2) collaboration among researchers, clinicians, and industry to integrate patient-derived data through sharing, transparency, and regulatory considerations; and (3) streamlining clinical efforts including biopsy, CNS-drug delivery, endpoint determination, and response monitoring. We highlight the importance of comprehensive collaboration to advance the understanding, diagnostics, and therapeutics for DMGs.
| Originele taal-2 | Engels |
|---|---|
| Pagina's (van-tot) | 1-5 |
| Aantal pagina's | 5 |
| Tijdschrift | Cancer Cell |
| Volume | 42 |
| Nummer van het tijdschrift | 1 |
| DOI's |
|
| Status | Gepubliceerd - 8 jan. 2024 |
Vingerafdruk
Duik in de onderzoeksthema's van 'A road map for the treatment of pediatric diffuse midline glioma'. Samen vormen ze een unieke vingerafdruk.Citeer dit
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver